Rusfertide & Hepcidin Mimetics in PV — PatSnap Eureka
Rusfertide & Hepcidin Mimetics: Patent Intelligence for Polycythemia Vera & Iron-Restricted Anemia
The hepcidin–ferroportin axis sits at the intersection of two clinically inverse disorders — pathological erythrocytosis in polycythemia vera and iron-sequestered anemia. Explore the patent and literature landscape powering next-generation iron regulatory therapeutics.
Two Clinically Inverse Disorders, One Molecular Axis
Life sciences IP intelligence reveals that polycythemia vera (PV) is described across multiple Protagonist Therapeutics filings as "a chronic, progressive trilineage clonal disorder signified by increased myeloid, erythroid, and megakaryocytic cell proliferation/accumulation," classified by the World Health Organization as a myeloproliferative neoplasm. PV is defined diagnostically by JAK2V617F or JAK2 exon 12 mutations alongside increased red cell mass and trilineage bone marrow hypercellularity. Clinical complications noted in retrieved filings include splenomegaly, thrombotic and bleeding events, and risk of leukemic transformation.
Iron-restricted and chronic disease anemias are described across FibroGen and Akebia Therapeutics filings as resulting from cytokine-driven suppression of EPO production (TNF-α, IL-1β, IFN-γ), impaired iron recycling from macrophages, reduced duodenal iron absorption, and elevated hepcidin levels that block ferroportin-mediated iron export. Functional iron deficiency — where systemic iron stores are adequate but delivery to erythroid precursors is impaired — is identified as a shared pathogenic feature across CKD-anemia, anemia of chronic disease (ACD), and ineffective erythropoiesis.
The central molecular axis in retrieved results is hepcidin (HAMP gene product) and its downstream target ferroportin (SLC40A1), with upstream regulators including BMP6/hemojuvelin (RGMc/HJV)/SMAD signaling, TMPRSS6 (matriptase-2), erythroferrone (ERFE), and the activin receptor type II (ActRIIA/ActRIIB) pathway. Research from the National Institutes of Health and peer-reviewed journals has established this axis as a druggable node for both iron restriction and iron mobilization strategies.
Six Mechanistic Approaches Targeting the Iron Regulatory Pathway
Retrieved patent filings across WO, EP, JP, AU, CN, and US jurisdictions reveal a multi-modality landscape converging on hepcidin and its upstream regulators.
Hepcidin Mimetics & Conjugated Analogs
The most PV-specific signal in this dataset originates from Protagonist Therapeutics, with at least five retrieved patent filings across WO, EP, IL, SG, and CA jurisdictions covering conjugated hepcidin mimetics explicitly indicated for treating polycythemia vera. These filings describe hepcidin analogues — including PEGylated or otherwise conjugated forms — designed to pharmacologically mimic the iron-restricting activity of endogenous hepcidin by driving ferroportin degradation, thereby reducing iron availability for pathological erythropoiesis. Rusfertide is the INN designation for the lead Protagonist compound in this class. Preclinical work (Casu et al., Blood. 2016;128(2):265-276) cited in filings shows minihepcidin administration significantly reduces splenomegaly and normalizes hematocrit in JAK2-mutant PV mouse models.
PV · Iron Overload · HemochromatosisTMPRSS6 (Matriptase-2) Inhibition
TMPRSS6 encodes matriptase-2, a serine protease that normally cleaves hemojuvelin (HJV/RGMc) to suppress hepcidin expression. Retrieved results highlight anti-TMPRSS6 antibodies from MabWell Therapeutics (JP 2023, AU 2025) that bind cell-surface TMPRSS6 to increase hepcidin expression, explicitly listing PV (JAK2/STAT5 pathway overactivation) as a target indication. ISIS Pharmaceuticals discloses lipid-formulated antisense compounds targeting TMPRSS6 mRNA to increase endogenous hepcidin levels in hemochromatosis and beta-thalassemia. Kymab Limited filings describe antibodies against matriptase-2 (MTP-2) for beta-thalassemia iron overload.
PV · Beta-Thalassemia · HemochromatosisRGMc/Hemojuvelin (HJV) Antagonism
Upstream of hepcidin, the BMP6/RGMc/SMAD signaling axis drives HAMP transcription. AbbVie Deutschland GmbH & Co. KG filings across CN and JP jurisdictions cover anti-RGMc antibodies that interrupt BMP–RGMc binding, thereby reducing hepcidin expression to mobilize iron in iron-restricted anemias. These filings explicitly target ACD, iron-resistant iron deficiency anemia (IRIDA), CKD-anemia, and beta-thalassemia. AbbVie filings also describe anti-RGMc antibody use in patients who are EPO-refractory, with language suggesting combination with reduced-dose ESA. A selective RGMc inhibitor filing from Gongshi Company (CN, 2021, active) extends this approach.
ACD · IRIDA · CKD-AnemiaRNA Interference Targeting HAMP
Alnylam Pharmaceuticals filings (EP 2014 and US 2014) describe lipid-formulated dsRNA agents targeting the hepcidin antimicrobial peptide (HAMP) gene to inhibit hepcidin expression and mobilize iron in iron-restricted anemia. Claimed indications include CKD, cancer, chronic inflammatory disease, rheumatoid arthritis, and iron-resistant iron deficiency anemia (IRIDA). Endpoint claims include ≥2-fold increases in serum iron and improvements in transferrin saturation. These filings are largely inactive in this dataset, reflecting early priority dates (2012–2014).
CKD · Rheumatoid Arthritis · IRIDAHIF Prolyl Hydroxylase Inhibitors (HIF-PHI)
The largest cluster of retrieved patents covers HIF-α stabilizers from FibroGen, Inc. (multiple CN, IL, AU, EP, CA, PT, HK, BR, WO, IN jurisdictions) and Akebia Therapeutics (vadadustat; TW, BR, MX, ID filings). These small molecules inhibit prolyl hydroxylase domain enzymes (PHDs), preventing HIF-α degradation, thereby elevating EPO production, reducing hepcidin expression, and improving iron mobilization. Retrieved Akebia filings explicitly reference efficacy observed for 24 to 52 weeks in CKD-anemia, conversion from ESA therapy, and dialysis patient populations. FibroGen filings note that HIF stabilization decreases hepcidin expression, enhancing iron mobilization.
CKD-Anemia · ACD · Advanced ClinicalActRII Antagonists for Ineffective Erythropoiesis
Acceleron Pharma filings (JP, CN jurisdictions, 2017–2021) describe ActRIIB polypeptides — including L79D variants fused to murine Fc — that antagonize activin/GDF signaling to promote late-stage erythroid maturation, reduce ineffective erythropoiesis, normalize iron overload, and increase hemoglobin. Data presented in retrieved filings includes correction of serum iron, serum ferritin, and transferrin saturation in Hbb-/- (beta-thalassemia) mouse models. Keros Therapeutics filings (JP, active 2023–2025) describe extracellular ActRII chimera–Fc fusion polypeptides for anemia, thrombocytopenia, neutropenia, and fibrosis.
Beta-Thalassemia · MDS · Ineffective ErythropoiesisIP Activity Across Hepcidin-Axis Therapeutic Modalities
Visualised from retrieved patent records across approximately 70 entries spanning WO, EP, JP, AU, CN, US, and additional jurisdictions in this dataset.
Hepcidin-Axis Patent Filings by Therapeutic Modality
HIF-PHI programs (FibroGen, Akebia) dominate by filing volume; Protagonist hepcidin mimetics represent the most concentrated PV-specific IP cluster.
Key Assignee IP Jurisdiction Breadth
FibroGen leads in raw jurisdiction count (12+); Protagonist's 6-jurisdiction prosecution signals active global PV-indication IP strategy for rusfertide.
Key Patent Holders in the Hepcidin & Iron Regulation Pipeline
Innovation activity in this dataset is strongly patent-driven, with academic literature contributing only 3 of approximately 70 retrieved entries.
| Assignee | Country | Primary Modality | Key Indications | IP Status (This Dataset) |
|---|---|---|---|---|
| Protagonist Therapeutics | US | Conjugated hepcidin mimetics (rusfertide class) | Polycythemia vera, hereditary hemochromatosis, iron overload | Active · 6+ families |
| FibroGen, Inc. | US | HIF-α stabilizers (HIF-PHI) | CKD-anemia, ACD, iron-restricted anemia | Mixed — some inactive (2004–2018) |
| Akebia Therapeutics | US | Vadadustat (HIF-PHI) | CKD-anemia, dialysis patients, ESA conversion | Active · 4 jurisdictions |
| Acceleron Pharma (MSD) | US | ActRIIB polypeptide antagonists | Beta-thalassemia, MDS, sideroblastic anemia, ineffective erythropoiesis | Active · JP & CN |
Emerging Multi-Pathway Strategies in the Hepcidin Pipeline
Retrieved results signal several mechanistically rationalized combination strategies across PV, beta-thalassemia, and MDS.
Hepcidin Mimetic + JAK2 Inhibition in PV
MabWell Therapeutics filings (AU, 2025) explicitly describe anti-TMPRSS6 antibodies for PV subjects "having JAK2/STAT5 overactivation," suggesting that iron restriction — via TMPRSS6 inhibition to raise hepcidin — could be combined with or used in patients receiving JAK2-directed therapy to provide orthogonal disease control. The Protagonist filings confirm PV diagnosis criteria include JAK2V617F or JAK2 exon 12 mutations.
MTP-2 Inhibitor + ActRII Ligand Trap (Beta-Thalassemia)
Kymab Limited JP filings explicitly claim that "combining MTP-2 inhibitors with activin receptor ligand traps or with erythropoietin provides additional therapeutic benefits" for beta-thalassemia, representing a mechanistically rationalized dual-pathway strategy: TMPRSS6 inhibition raises hepcidin (limiting iron uptake) while ActRII antagonism corrects ineffective erythropoiesis.
HIF-PHI + Iron Supplementation
FibroGen filings describe co-administration of HIF stabilizers with iron and B vitamins to optimize erythropoietic response, and note that HIF-PHI reduces hepcidin, facilitating ferroportin-mediated iron export — a mechanistic complement to exogenous iron supplementation in CKD-anemia and ACD settings.
RGMc Antagonism + Reduced-Dose ESA
AbbVie filings describe anti-RGMc antibody use in patients who are EPO-refractory, with language suggesting combination with reduced-dose ESA. This approach targets the BMP–RGMc N-terminal binding to prevent SMAD-mediated HAMP transcription, mobilizing iron for erythroid use even in ESA-resistant functional iron deficiency.
What the IP Landscape Signals for Investors & R&D Teams
Protagonist Therapeutics holds the most concentrated PV-specific hepcidin mimetic IP in this dataset, with filings across multiple jurisdictions still pending (EP, IL, SG, CA, CN), representing an active IP prosecution strategy likely designed to protect rusfertide globally across the PV indication. Competitors or licensees in this space should monitor continuation filing activity. The PatSnap patent analytics platform enables real-time tracking of continuation filings and family expansions.
The TMPRSS6 axis is emerging as a second-generation iron regulation target in this dataset, with activity from both an ASO modality (Ionis/ISIS, active EP) and antibody modalities (MabWell, active JP/AU), and with explicit PV indications claimed — suggesting this target may represent a competitive alternative to direct hepcidin mimicry, particularly for oral or longer-acting antibody formats. According to European Patent Office records, these filings signal active international prosecution strategies.
HIF-PHI (FibroGen, Akebia) patents are predominantly inactive in this dataset, reflecting a maturing or expiring IP estate in some jurisdictions; opportunities may exist for formulation, combination, or biomarker patents around approved or late-stage HIF-PHI compounds in iron-restricted anemia. The PatSnap customer success library documents how pharma teams have identified white-space opportunities in maturing IP estates.
Academic literature in this dataset is sparse relative to patent filings — only 3 of approximately 70 retrieved entries — indicating that core innovation in hepcidin mimetics and upstream iron regulators is driven by commercial R&D rather than academic publication, consistent with the competitive and proprietary nature of peptide analog and antibody engineering. For developer access to patent data APIs, see PatSnap Open.
Near-Clinical Evidence from Retrieved Patent & Literature Records
Retrieved results provide the following clinical or near-clinical signals — note that no retrieved results contain primary human clinical trial outcome data for rusfertide specifically.
24–52 Week CKD-Anemia Efficacy Language
Multiple retrieved Akebia filings explicitly reference "efficacy observed for 24 to 52 weeks" in CKD-anemia, conversion from ESA therapy, and dialysis patient populations, with claims structured around specific hemoglobin correction and maintenance endpoints. This language is consistent with clinical trial experience, though the retrieved patents do not provide primary trial outcome data.
CKD-Anemia · ESA Conversion · Advanced ClinicalJAK2-Mutant PV Mouse Model: Hematocrit Normalization
Retrieved Protagonist filings reference published preclinical data (Casu et al., Blood. 2016;128(2):265-276) showing normalization of hematocrit and reduction of splenomegaly in JAK2-mutant PV mice following minihepcidin administration. The filings contain pharmacological design elements — conjugation strategies for half-life extension — consistent with preparation for clinical translation and IND-enabling rationale.
PV · Preclinical-to-Clinical · IND-EnablingBeta-Thalassemia Mouse Model: Iron Parameter Normalization
Retrieved Acceleron JP and CN filings present quantified preclinical data — including serum iron, ferritin, transferrin saturation normalization in Hbb-/- (beta-thalassemia) mice — and reference patient selection criteria based on ring sideroblast percentage (≥10–20%), consistent with clinical trial eligibility design. Filings also describe correction of bone mineral density alongside erythroid parameters.
Beta-Thalassemia · MDS · Ring SideroblastsNovel Hepcidin Regulatory Mechanisms Highlighted at EHA 2023
A retrieved academic record from Vita-Salute San Raffaele University (Milan) reporting on European Hematology Association (EHA) 2023 presentations notes that novel hepcidin regulatory mechanisms and therapeutic modulation strategies were highlighted in oral sessions, with presentations covering anemia in inflammation, chronic disease, and beta-thalassemia contexts — signaling growing clinical community interest in this target class.
EHA 2023 · Hepcidin Regulation · Inflammation AnemiaTrack clinical-stage hepcidin mimetic programs as they advance
PatSnap Eureka monitors patent prosecution activity as a leading indicator of pipeline advancement.
Rusfertide & Hepcidin Mimetics in PV — key questions answered
Rusfertide is the INN designation for the lead Protagonist Therapeutics compound in the conjugated hepcidin mimetic class. These hepcidin analogues — including PEGylated or otherwise conjugated forms — are designed to pharmacologically mimic the iron-restricting activity of endogenous hepcidin by driving ferroportin degradation, thereby reducing iron availability for pathological erythropoiesis in polycythemia vera.
A key biological rationale cited across retrieved Protagonist filings references preclinical work (Casu et al., Blood. 2016;128(2):265-276): in JAK2-mutant PV mouse models, minihepcidin administration significantly reduces splenomegaly and normalizes hematocrit, establishing proof-of-concept for iron restriction as a disease-modifying strategy in PV.
TMPRSS6 encodes matriptase-2, a serine protease that normally cleaves hemojuvelin (HJV/RGMc) to suppress hepcidin expression. Inhibiting TMPRSS6 — via antisense oligonucleotides or antibodies — indirectly elevates endogenous hepcidin levels, making it a target for polycythemia vera and iron overload disorders.
HIF prolyl hydroxylase inhibitors (HIF-PHIs) stabilize HIF-alpha, elevating EPO production, reducing hepcidin expression, and improving iron mobilization. Retrieved FibroGen filings note that HIF stabilization decreases hepcidin expression, enhancing iron mobilization — relevant to functional iron deficiency in CKD and anemia of chronic disease.
Protagonist Therapeutics holds the most concentrated PV-specific hepcidin mimetic IP in this dataset, with at least 6 patent families across WO, EP, IL, SG, CA, and CN jurisdictions covering conjugated hepcidin mimetics for PV and iron overload. MabWell Therapeutics is emerging with anti-TMPRSS6 antibody filings explicitly listing PV as a target indication.
Retrieved results signal several combination strategies: hepcidin mimetic plus JAK2 inhibition in PV; MTP-2 (TMPRSS6) inhibitor combined with activin receptor ligand traps for beta-thalassemia; HIF-PHI with iron supplementation; RGMc antagonism with reduced-dose ESA; and erythroferrone/SF3B1 biomarker-guided treatment selection in MDS.
Still have questions? Let PatSnap Eureka search the patent and literature database for you.
Ask PatSnap Eureka About This PipelineAccelerate Your Hepcidin & Iron Regulatory Research with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D across hematology, iron biology, and rare blood disorders.
References
- Conjugated hepcidin mimetics
- Conjugated hepcidin mimetics
- Conjugated hepcidin mimetics
- Conjugated hepcidin mimetics
- Conjugated hepcidin mimetics
- Compositions and methods for treating iron overload
- Compositions and methods for treating iron overload
- Anti-tmprss6 antibodies and uses thereof
- Anti-TMPRSS6 antibody and its uses
- Modulation of TMPRSS6 expression
- Treatment of physiological iron excess
- Treatment of physiological iron overload
- Compositions and methods for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
- Compositions and Method for Inhibiting Hepcidin Antimicrobial Peptide (HAMP) or HAMP-Related Gene Expression
- Methods and compositions for treating ineffective erythropoiesis
- Methods for treating myelodysplastic syndromes and sideroblastic anemia
- Activin-ActRII antagonists and uses for treating anemia
- Activin receptor type II chimeras and methods of use thereof
- Composition and method for diagnosing and treating iron-related disorders
- RGMc selective inhibitors and uses thereof
- Use of HIF alpha stabilizers for enhancing erythropoiesis
- Therapeutic methods using vadadustat
- European Patent Office — Patent Search
- National Institutes of Health — Iron Metabolism Research
- World Health Organization — Myeloproliferative Neoplasm Classification
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full clinical pipeline, regulatory landscape, or global IP portfolio.
PatSnap Eureka searches patents and research to answer instantly.